Active CNS leukemia. research hub

Phase 1b study to evaluate MK 0482 for Relapsed/Refractory AML/CMML

This early-stage study is looking at a new medicine called MK 0482 for adults with certain types of blood cancer (AML or CMML) that have come back after treatment or haven't responded well. It aims to see if the medicine is safe and how it works.